Abstract
Cultures of primary hepatocytes and hepatoma cell line HepG2 are frequently used in in vitro models for human biotransformation studies. In this study, we characterized and compared the capacity of these model systems to indicate the presence of different classes of promutagens. Genotoxic sensitivity, enzyme activity, and gene expression were monitored in response to treatment with food promutagens benzo[a]pyrene, dimethylnitrosamine (DMN), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). DNA damage could be detected reliably with the comet assay in primary human hepatocytes, which were maintained in sandwich culture. All three promutagens caused DNA damage in primary cells, but in HepG2 no genotoxic effects of DMN and PhIP could be detected. We supposed that the lack of specific enzymes accounts for their inability to process these promutagens. Therefore, we quantified the expression of a broad range of genes coding for drug-metabolizing enzymes with real-time reverse transcription-polymerase chain reaction. The genes code for cytochromes P450 and, in addition, for a series of important phase II enzymes. The expression level of these genes in human hepatocytes was similar to those previously reported for human liver samples. On the other hand, expression levels in HepG2 differed significantly from that in human. Activity and expression, especially of phase I enzymes, were demonstrated to be extremely low in HepG2 cells. Up-regulation of specific genes by test substances was similar in both cell types. In conclusion, human hepatocytes are the preferred model for biotransformation in human liver, whereas HepG2 cells may be useful to study regulation of drug-metabolizing enzymes.
Footnotes
-
↵1 Abbreviations used are: B[a]P, benzo[a]pyrene; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; DMN, dimethylnitrosamine; RT-PCR, reverse transcription-polymerase chain reaction; DMSO, dimethyl sulfoxide; 3-MC, 3-methylcholanthrene; PBS, phosphate-buffered saline; EROD, 7-ethoxyresorufin O-deethylation; ECOD, 7-ethoxycoumarin O-deethylation; NAT, N-acetyltransferase; HMBS, hydroxymethylbilane synthase; HPRT, hypoxanthine phosphoribosyltransferase; ATP5O, ATP synthase; EF1A1, elongation factor 1 alpha; NQO1, NADP-quinone reductase 1; SULT, sulfotransferase; GAPD, glyceraldehyde-3-phosphate dehydrogenase; LAP, liver-enriched activator protein; LIP, liver-enriched inhibitor protein; C/EBP, CCAAT/enhancer-binding protein.
-
This work was supported by the European Union, HEPADNA Contract QLRT-1999-00810 and by a fellowship from the Dr. Hilmer-Stiftung for S.W.
- Received February 26, 2003.
- Accepted April 24, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|